argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

argenx SE announced 20 presentations of clinical trial and real-world data from studies of VYVGART® and VYVGART Hytrulo® in neuromuscular autoimmune disease.